skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Current and emerging therapeutic options for the treatment of chronic chagasic cardiomyopathy

Review

(1708) Views  (585) Full article downloads

Authors: Claudio A Muratore, Adrian Baranchuk

Published Date July 2010 Volume 2010:6 Pages 593 - 601
DOI: http://dx.doi.org/10.2147/VHRM.S8355

Claudio A Muratore1, Adrian Baranchuk2

1Department of Cardiology, Arrhythmia Service, Hospital Fernandez, Buenos Aires, Argentina; 2Department of Cardiology, Arrhythmia Service, Kingston General Hospital, Kingston, Ontario, Canada

Abstract: Chagas’ disease is an endemic disease in Latin America caused by a unicellular parasite (Trypanosoma cruzi) that affects almost 18 million people. This condition involves the heart, causing heart failure, arrhythmias, heart block, thromboembolism, stroke, and sudden death. In this article, we review the current and emerging treatment of Chagas’ cardiomyopathy focusing mostly on management of heart failure and arrhythmias. Heart failure therapeutical options including drugs, stem cells and heart transplantation are revised. Antiarrhythmic drugs, catheter ablation, and intracardiac devices are discussed as well. Finally, the evidence for a potential role of specific antiparasitic treatment for the prevention of cardiovascular disease is reviewed.

Keywords: chronic chagasic cardiomyopathy, emerging therapeutic options







Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Heart rate control with adrenergic blockade: Clinical outcomes in cardiovascular medicine
Amiodarone for the treatment and prevention of ventricular fibrillation and ventricular tachycardia
Cardiac risk stratification: Role of the coronary calcium score
Recent advances in the management of chronic stable angina I: Approach to the patient, diagnosis, pathophysiology, risk stratification, and gender disparities
Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization
Management of acute attacks of hereditary angioedema: potential role of icatibant
Nonsteroidal anti-inflammatory drug gastropathy: new avenues for safety
Effect of vascular burden as measured by vascular indexes upon vascular dementia: a matched case-control study
Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy?
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University